Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis [0.03%]
纳利珠单抗与复发型多发性硬化患者其他高效疗法的费用后果分析
Luca Prosperini,Vincenzo Brescia Brescia Morra,Carla Fornari et al.
Luca Prosperini et al.
Background: Advances in the availability and regimen optimization of highly effective disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS) have led to questions about their comparative wor...
Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness Analyses [0.03%]
SGLT2i治疗2型糖尿病的经济价值异质性：成本效益亚组分析模型
Kah Suan Chong,Chun-Ting Yang,Chi-Chuan Wang et al.
Kah Suan Chong et al.
Background and objective: Although heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been revealed, the heterogeneous economic value of SGLT2is in real-world type 2 diabetes (T2D)...
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens [0.03%]
经济与环境并重：评估PD-1和PD-L1抑制剂替代给药方案的效果与成本
Leo Karlsson,Joseph Ciccolini,Rob Ter Heine et al.
Leo Karlsson et al.
Background: Immune checkpoint inhibitors (ICIs) are clinically beneficial but associated with high costs that represent a growing challenge for healthcare budgets and may affect affordability, especially in resource-limit...
Anirban Basu,Simu K Thomas,Richard H Chapman et al.
Anirban Basu et al.
Manufacturers of orphan drugs face several obstacles in meeting health technology assessment requirements because of poor availability of natural history data, small sample sizes, single-arm trials, and a paucity of established disease-spec...
Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention [0.03%]
心血管病预防卫生经济学宣言概要
Zanfina Ademi,Sheridan E Rodda,Karl Vivoda et al.
Zanfina Ademi et al.
Cardiovascular disease (CVD) is a major contributor to the health and economic burden of disease globally. In this paper we discuss the literature on the health economics of the prevention and early intervention in CVD. We reveal the large ...
Nan Luo,Annushiah Vasan Thakumar,Ling Jie Cheng et al.
Nan Luo et al.
Objectives: The EQ-5D-5L is a multi-attribute utility instrument recommended by many health technology assessment agencies. This study aimed to develop an EQ-5D-5L value set for Singapore. ...
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease [0.03%]
中重度克罗恩病治疗方案的成本效用分析
Matthijs M Versteegh,Simone A Huygens,Inigo Bermejo et al.
Matthijs M Versteegh et al.
Objectives: The clinical pathway for patients with moderate-to-severe Crohn's disease (CD) typically includes sequential pharmacologic treatment as well as surgery, but positioning of different therapies within these sequ...
Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children [0.03%]
通过离散选择实验在成人、青少年和儿童中诱发并定位健康状况偏好
Shitong Xie,Tianxin Pan,Juan Manuel Ramos-Goni et al.
Shitong Xie et al.
Objective: We aimed to compare EQ-5D-Y-5L health state preferences among children, adolescents, and adults in Canada using a discrete choice experiment (DCE), and to explore the feasibility of a rescaling latent DCE using...
Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review [0.03%]
转移性雄激素敏感前列腺癌成本效益评价的全面框架的发展：系统回顾的启示
Christopher G Fawsitt,Elaine Gallagher,Alka Singh et al.
Christopher G Fawsitt et al.
Background and objectives: Metastatic castration-sensitive prostate cancer (mCSPC) imposes a significant economic burden and necessitates more cost-effective treatment strategies. The variability among the components of p...
Lifetime Healthcare and Long-Term Care Costs of Heart Failure: Estimates Using Administrative Data from Hospitalized Patients in the Netherlands [0.03%]
基于荷兰住院患者管理数据的心力衰竭终身医疗和长期照护成本估算
Hamraz Mokri,Pieter van Baal,Maureen Rutten-van Mölken
Hamraz Mokri
Background and objective: Heart failure (HF) is a complex clinical syndrome associated with high mortality and extensive healthcare use. Using longitudinal data, we aimed to estimate the lifetime healthcare and long-term ...